Memorial Sloan Kettering Cancer Center (MSK) and Quantoom Biosciences have entered into a non-exclusive research license and supply agreement to support the development of personalized cancer therapies. The collaboration will use Quantoom’s lipid nanoparticle (LNP) formulation technology, Ncapsulate QCX-002, for research and development at MSK.
Under this agreement, MSK will receive supplies of Ncapsulate QCX-002 from Quantoom to develop therapeutic products targeting human cancers. The deal also includes an option for MSK to access future developments in Quantoom’s proprietary QCX library. In addition, MSK will assess other RNA manufacturing technologies from Quantoom for possible broader collaboration in RNA therapeutics.
The Olayan Center for Cancer Vaccines (OCCV) at MSK will lead these efforts as part of its work on personalized cancer immunotherapies. During the initial phase, OCCV aims to use QCX-002 in at least one RNA medicine that is expected to enter Phase I clinical trials.
“This agreement with MSK marks a major milestone for Quantoom and validates the potential of our QCX formulation chemistries in human therapeutic applications,” said José Castillo, CEO of Quantoom Biosciences. “It is an honor to collaborate with one of the most prestigious cancer research institutions in the world to help advance personalized RNA-based medicines.”
“We are thrilled to partner with Quantoom to advance personalized therapeutics for patients battling deadly cancers,” said Vinod Balachandran, MD, Director of the OCCV at MSK. “The powerful union of cutting-edge innovation and deep expertise, such as this, is precisely what’s needed to accelerate the development of breakthrough cancer medicines.”
Quantoom Biosciences specializes in providing RNA solutions for mRNA- and saRNA-based vaccines and therapeutics through its N-Force toolbox. This includes Ncode for sequence design and optimization, Ntensify for RNA production, and Ncapsulate for LNP formulation. Since launching its Ntensify solution in 2023, the company has seen global adoption due to its integrated approach to scalable RNA production.
Founded in 1884 and located in New York City, Memorial Sloan Kettering Cancer Center is recognized as a leading institution in cancer treatment and research. The center’s current president is Selwyn M. Vickers. In 2022, MSK reported conducting over 26,000 surgeries and admitting more than 24,000 patients according to its annual report.
For more information about Quantoom Biosciences, visit www.quantoom.com
